Our research finds that Life Sciences CEOs are confident in industry growth fueled by innovation, technological advancement, and operational efficiency. There is a strong appetite for mergers and acquisitions, substantial investments in AI and digitalization, and a critical need to empower the workforce to navigate rapid change. While sustainability and ESG remain high on the agenda for Life Sciences organizations globally, there are shifting priorities across regions.

Key findings

Important capabilities for Life Sciences companies in the next three years.

Organizations that have already adapted their growth strategies due to interrelated challenges

Life sciences: 80%
Cross sector average: 72%

86%

have a moderate-to-high appetite for M&A over the next three years

25%

integrate the costs and ROI of sustainability initiatives into every major capital investment

73%

expect most corporate staff to be working in hybrid models within three years

Despite market uncertainty, industry confidence is rising, with 83% of Life Sciences CEOs optimistic about growth as they balance innovation with operational efficiency. CEOs are moving beyond pilots and operationalizing AI while investing in workforce readiness and upskilling. Sustainability and ESG remain high on the agenda, shifting from compliance to strategy, with approaches tailored by region.

Koen Van Ende,
Partner, Head of Life Sciences
KPMG in Belgium

Why download the report?

By downloading the 2025 Life Sciences CEO Outlook, you’ll unlock unique perspectives on:

  • Industry growth prospects and drivers, M&A appetite, and operational challenges
  • AI and other capabilities investment
  • Workforce challenges and transformation
  • Evolution of ESG strategies

Enhance your strategic planning with expert analysis and actionable insights.